02616.HK
CStone Pharmaceuticals
HKSE · Healthcare · Biotechnology · CN
HKD 4.94
+4.33%Year over year
Reported trailing growth
- Revenue
- +137.6%
- EBITDA
- -81.1%
- EBIT
- -61.0%
- EPS
- -46.9%
- Free cash flow
- +38.7%
- Operating cash flow
- +38.7%
Forward estimates
Based on analyst estimates
- Revenue
- +8.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -17.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026